Epidermal growth factor receptor tyrosine kinase inhibitorsRANSON, M.British journal of cancer. 2004, Vol 90, Num 12, pp 2250-2255, issn 0007-0920, 6 p.Article

Les recensions des archives des ministères collationnés par les diverses missions d'archives et publiées par l'Institut d'histoire du temps présentRANSON, M.Le Mouvement social. 1991, Num 157, pp 85-86, issn 0027-2671Article

PHARMACOLOGICAL PROPERTIES OF A NEW ANTIINFLAMMATORY AGENT: 2-(2-ISOPROPYL-5-INDANYL) PROPIONIC ACID (UP 517-03)HERTZ F; RANSON M; LWOFF JM et al.1980; ARZNEIM.-FORSCH.; ISSN 0004-4172; DEU; DA. 1980; NO 9; PP. 1549-1557; ABS. GER; BIBL. 14 REF.Article

The topology of plasminogen binding and activation on the surface of human breast cancer cellsANDRONICOS, N. M; RANSON, M.British journal of cancer. 2001, Vol 85, Num 6, pp 909-916, issn 0007-0920Article

Gefitinib, a novel, orally administered agent for the treatment of cancerRANSON, M; WARDELL, S.Journal of clinical pharmacy and therapeutics (Print). 2004, Vol 29, Num 2, pp 95-103, issn 0269-4727, 9 p.Article

Development of interactive graphics within the National Coal Board = Le développement de graphiques interactifs au sein du National Coal BoardHARTLEY, D; RANSON, M. A.Application of computers and mathematics in the mineral industries. International Symposium. 18. 1984, pp 201-210Conference Paper

Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1DANSON, S. J; JOHNSON, P; ROBSON, L et al.Annals of oncology. 2011, Vol 22, Num 7, pp 1653-1660, issn 0923-7534, 8 p.Article

In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancersALLEN, B. J; RIZVI, S; LI, Y et al.Critical reviews in oncology/hematology. 2001, Vol 39, Num 1-2, pp 139-146, issn 1040-8428Conference Paper

Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatography assay for the novel antitumour agent CT2584 in human plasmaKHAN, P; ABBAS, S; CHEESEMAN, S et al.Journal of chromatography. B, Biomedical sciences and applications. 1999, Vol 721, Num 2, pp 279-284, issn 1387-2273Article

Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancerVAN HOEF, M. E. H. M; BAUMANN, I; HOWELL, A et al.Annals of oncology. 1994, Vol 5, Num 3, pp 217-224, issn 0923-7534Article

Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinomaMURPHY, D; LIND, M. J; PRENDIVILLE, J et al.European journal of cancer (1990). 1992, Vol 28A, Num 4-5, pp 870-872, issn 0959-8049Article

Intensive therapy for small-cell cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapyPRENDIVILLE, J; RADFORD, J; THATCHER, N et al.Journal of clinical oncology. 1991, Vol 9, Num 8, pp 1446-1452, issn 0732-183XArticle

Double-blind placebo controlled study of vancomycin prophylaxis for central venous catheter insertion in cancer patients = Etude en double aveugle, contrôlée contre placebo, de la prophylaxie par vancomycine lors de la mise en place de cathéters veineux centraux chez les patients cancéreuxRANSON, M; OPPENHEIM, B; JACKSON, A et al.The Journal of hospital infection. 1990, Num 15, pp 95-102, issn 0195-6701Article

Effects of various compounds on the accumulation of macrophages in miceHERTZ, F; RANSON, M; CHEVRIER, M. M et al.Archives internationales de pharmacodynamie et de thérapie. 1984, Vol 268, Num 1, pp 155-164, issn 0003-9780Article

Biomarker method validation in anticancer drug developmentCUMMINGS, J; WARD, T. H; GREYSTOKE, A et al.British journal of pharmacology. 2008, Vol 153, Num 4, pp 646-656, issn 0007-1188, 11 p.Article

A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancerBAKA, S; RANSON, M; LORIGAN, P et al.European journal of cancer (1990). 2005, Vol 41, Num 11, pp 1547-1550, issn 0959-8049, 4 p.Article

Randomized phase II study of Temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanomaDANSON, S; LORIGAN, P; ARANCE, A et al.Journal of clinical oncology. 2003, Vol 21, Num 13, pp 2551-2557, issn 0732-183X, 7 p.Article

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphomaBLACKHALL, F. H; RANSON, M; RADFORD, J. A et al.British journal of cancer. 2001, Vol 84, Num 4, pp 465-469, issn 0007-0920Article

Phases I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumoursCHEESEMAN, S. L; BRANNAN, M; MCGOWN, A et al.British journal of cancer. 2000, Vol 83, Num 12, pp 1599-1606, issn 0007-0920Article

A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma : A comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervalsWRIGLEY, E; WEAVER, A; RADFORD, J. A et al.Annals of oncology. 1996, Vol 7, Num 7, pp 705-711, issn 0923-7534Article

Liposomal drug deliveryRANSON, M; HOWELL, A; CHEESEMAN, S et al.Cancer treatment reviews. 1996, Vol 22, Num 5, pp 365-379, issn 0305-7372Article

A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cyclesMURPHY, D; CROWTHER, D; RENNINSON, J et al.Annals of oncology. 1993, Vol 4, Num 5, pp 377-383, issn 0923-7534Article

Extracellular matrix modulates the function of human melanocytes but not melanoma cellsRANSON, M; POSEN, S; MASON, R. S et al.Journal of cellular physiology. 1988, Vol 136, Num 2, pp 281-288, issn 0021-9541Article

Effects of calcium-antagonists on passive cutaneous anaphylaxis in the ratHERTZ, F; RANSON, M; DEFEUDIS, F. V et al.International journal of immunopharmacology. 1983, Vol 5, Num 5, pp 427-429, issn 0192-0561Article

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumoursDEAN, E; MIDDLETON, M. R; PWINT, T et al.British journal of cancer. 2012, Vol 106, Num 3, pp 468-474, issn 0007-0920, 7 p.Article